Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model

Behavioural Brain Research

Volumn 312, Issue , 2016, Pages 93-101

  Sahin, Ceren ^a   Doostdar, Nazanin ^b   Neill, Joanna C ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Affective and cognitive bias; Animal model; Negative symptoms; NMDA receptor; PCP; Schizophrenia

Indexed keywords

PHENCYCLIDINE;

ADULT; AFFECT; AFFECTIVE BIAS TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE BIAS; COGNITIVE BIAS TEST; COGNITIVE DEFECT; CONTROLLED STUDY; DECISION MAKING; EMOTIONAL BIAS; FEMALE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OPTIMISM; PRIORITY JOURNAL; RAT; REWARD; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; PSYCHOLOGY; SCHIZOPHRENIA;

AFFECT; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; PHENCYCLIDINE; RATS; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84975865459     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.06.021     Document Type: Article

References (45)

1. [1] Abdul-Monim, Z., Neill, J.C., Reynolds, G.P., Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. 21 (2007), 198–205.
2. [2] Adams, R., David, A.S., Patterns of anterior cingulate activation in schizophrenia: a selective review. Neuropsychiatr. Dis. Treat. 3 (2007), 87–101.
3. [3] Aleman, A., Kahn, R.S., Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?. Prog. Neurobiol. 77 (2005), 283–298.
4. [4] Anderson, M.H., Munafo, M.R., Robinson, E.S.J., Investigating the psychopharmacology of cognitive affective bias in rats using an affective tone discrimination task. Psychopharmacology (Berl.) 226 (2013), 601–613.
5. [5] Arango, C., Garibaldi, G., Marder, S.R., Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr. Res. 150 (2013), 346–352.
6. [6] Barnes, S.A., Der-Avakian, A., Markou, A., Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur. Neuropsychopharm. 24 (2014), 744–758.
7. [7] Barnes, S.A., Sawiak, S.J., Caprioli, D., Jupp, B., Buonincontri, G., Mar, A.C., Harte, M.K., Fletcher, P.C., Robbins, T.W., Neill, J.C., Dalley, J.W., Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int. J. Neuropsychopharm. 18 (2014), 1–12.
8. [8] Bateson, M., Matheson, S.M., Performance on a categorisation task suggests that removal of environmental enrichment induces ‘pessimism' in captive European starlings (Sturnus vulgaris). Anim. Welfare 16 (2007), 33–36.
9. [9] Blanchard, J.J., Cohen, A.S., The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr. Bull. 32 (2006), 238–245.
10. [10] Bouras, C., Kovari, E., Hof, P.R., Riederer, B.M., Giannakopoulos, P., Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol. 102 (2001), 373–379.
11. [11] Brilot, B.O., Asher, L., Bateson, M., Stereotyping starlings are more ‘pessimistic’. Anim. Cog. 13 (2010), 721–731.
12. [12] Brilot, B.O., Normandale, C.L., Parkin, A., Bateson, M., Can we use starlings’ aversion to eyespots as the basis for a novel ‘cognitive bias’ task?. Appl. Anim. Behav. Sci. 118 (2009), 182–190.
13. [13] Brydges, N.M., Leach, M., Nicol, K., Wright, R., Bateson, M., Environmental enrichment induces optimistic cognitive bias in rats. Anim. Behav. 81 (2011), 169–175.
14. [14] Burman, O.H.P., Parker, R.M.A., Paul, E.S., Mendl, M., Sensitivity to reward loss as an indicator of animal emotion and welfare. Biol. Lett. 4 (2008), 330–333.
15. [15] Clayton, J.A., Collins, F.S., NIH to balance sex in cell and animal studies. Nature 509 (2014), 282–283.
16. [16] Davis, M.C., Horan, W.P., Marder, S.R., Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur. Neuropsychopharm. 24 (2014), 788–799.
17. [17] Drevets, W.C., Savitz, J., The subgenual anterior cingulate cortex in mood disorders. Cns. Spectrums 13 (2008), 663–681.
18. [18] Ende, G., Braus, D.F., Walter, S., Weber-Fahr, W., Soher, B., Maudsley, A.A., Henn, F.A., Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 41 (2000), 389–395.
19. [19] Foussias, G., Agid, O., Fervaha, G., Remington, G., Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur. Neuropsychopharm. 24 (2014), 693–709.
20. [20] Foussias, G., Siddiqui, I., Fervaha, G., Agid, O., Remington, G., Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. J. Psychopharmacol. 29 (2015), 116–126.
21. [21] Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., McGuire, P., Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr. Bull. 41 (2015), 892–899.
22. [22] Grayson, B., Leger, M., Adamson, L., Harte, M., Neill, J.C., Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav. Brain Res. 285 (2015), 176–193.
23. [23] Gururajan, A., Taylor, D.A., Malone, D.T., Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav. Pharmacol. 21 (2010), 690–709.
24. [24] Harding, E.J., Paul, E.S., Mendl, M., Animal behavior – Cognitive bias and affective state. Nature, 427, 2004, 312.
25. [25] Kirkpatrick, B., Fenton, W.S., Carpenter, W.T., Marder, S.R., The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32 (2006), 214–219.
26. [26] Knuesel, I., Chicha, L., Britschgi, M., Schobel, S.A., Bodmer, M., Hellings, J.A., Toovey, S., Prinssen, E.P., Maternal immune activation and abnormal brain development across CNS disorders. Nat. Rev. Neurol. 10 (2014), 643–660.
27. [27] Kring, A.M., Barch, D.M., The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur. Neuropsychopharm. 24 (2014), 725–736.
28. [28] Leger, M., Alvaro, G., Large, C., Harte, M., Neill, J.C., AUT6, a novel Kv3 channel modilator, reverses cognitive and neurobiological dysfunction in a rat model of relevance to schizophrenia symptomatology. Eur. Neuropsychopharm., 25, 2015, S480.
29. [29] Lydall, E.S., Gilmour, G., Dwyer, D.M., Analysis of licking microstructure provides no evidence for a reduction in reward value following acute or sub-chronic phencyclidine administration. Psychopharmacology (Berl.) 209 (2010), 153–162.
30. [30] Matheson, S.M., Asher, L., Bateson, M., Larger, enriched cages are associated with ‘optimistic’ response biases in captive European starlings (Sturnus vulgaris). Appl. Anim. Behav. Sci. 109 (2008), 374–383.
31. [31] McLean, S.L., Beck, J.R., Woolley, M.L., Neill, J.C., A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav. Brain. Res. 189 (2008), 152–158.
32. [32] McLean, S.L., Grayson, B., Idris, N.F., Lesage, A.S., Pemberton, D.J., Mackie, C., Neill, J.C., Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur. Neuropsychopharm. 21 (2011), 333–343.
33. [33] McLean, S.L., Idris, N.F., Woolley, M.L., Neill, J.C., D-1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur. Neuropsychopharm. 19 (2009), 440–450.
34. [34] Meltzer, H.Y., Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 64 (2013), 393–406.
35. [35] Mendl, M., Burman, O.H.P., Parker, R.M.A., Paul, E.S., Cognitive bias as an indicator of animal emotion and welfare: emerging evidence and underlying mechanisms. Appl. Anim. Behav. Sci. 118 (2009), 161–181.
36. [36] Morris, B.J., Cochran, S.M., Pratt, J.A., PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5 (2005), 101–106.
37. [37] Moser, P., Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia. Eur. Neuropsychopharm. 24 (2014), 774–787.
38. [38] Neill, J.C., Barnes, S., Cook, S., Grayson, B., Idris, N.F., McLean, S.L., Snigdha, S., Rajagopal, L., Harte, M.K., Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 128 (2010), 419–432.
39. [39] Neill, J.C., Harte, M.K., Haddad, P.M., Lydall, E.S., Dwyer, D.M., Acute and chronic effects of NMDA receptor antagonists in rodents: relevance to negative symptoms of schizophrenia: a translational link to humans. Eur. Neuropsychopharm. 24 (2014), 822–835.
40. [40] Stevens, F.L., Hurley, R.A., Taber, K.H., Anterior cingulate cortex: unique role in cognition and emotion. J. Neuropsych. 23 (2011), 120–125.
41. [41] Stuart, S.A., Butler, P., Munafo, M.R., Nutt, D.J., Robinson, E.S., A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology 38 (2013), 1625–1635.
42. [42] Sutcliffe, J.S., Marshall, K.M., Neill, J.C., Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behav. Brain Res. 177 (2007), 117–125.
43. [43] Tsapakis, E.M., Dimopoulou, T., Tarazi, F.I., Clinical management of negative symptoms of schizophrenia: an update. Pharmacol. Ther. 153 (2015), 135–147.
44. [44] Wilson, C.A., Koenig, J.I., Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur. Neuropsychopharm. 24 (2014), 759–773.
45. [45] Young, J.W., Powell, S.B., Risbrough, V., Marston, H.M., Geyer, M.A., Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122 (2009), 150–202.